We invest in synthetic biology innovations

To bring disruptive technologies in health, environment and sustainable manufacturing to market.

Science is in our DNA

Most of our team has advanced training in science and our Science Advisory Board is top-notch; We promote science-based pitch competitions to discover and support ambitious SynBio projects

Highly specialized

100% dedicated to investment in SynBio

Our network

Spans many niche areas of SynBio research and commercialization across Europe. We nurture it through our Annual SynBio Day and other activities

Rare cross-sector investment portfolio

Our investments are at different stages of growth and span health, environment and sustainable manufacturing

We’re investing in the next big revolution

Synthetic biology and applies techniques from engineering and computer sciences to biology. We believe it will revolutionize how we live, eat, and protect our planet

60%

of the materials we use could be made using biological means

Over 400

use cases spanning applications in healthcare, manufacturing, agriculture, energy and the environment

Up to 4Tn US$

the value projection of direct economic impact of innovation in SynBio is estimated to be by 2040

Our investment model

We act as a bridge between academia and industry, financing and developing synthetic biology innovation across Europe, UK, and Israel through an innovative investment model geared towards very early-stage start-ups and more mature SynBio companies

25 M
Launched in 2021
1
Companies financed
1
Biotech Start-Up Studios
1 st
SPAC dedicated to bio-manufacturing in Europe
Editions of our International Conference SynBio Day
> 150
Scientific projects evaluated

Our areas of focus

We’re convinced that the right SynBio innovations will provide solutions to major challenges of our time.

Homepage-health-test

Health

We’ve made 9 investments in the health space, including a SPAC. These span biomanufacturing, gene and cell therapies, microbial drugs, DNA synthesis, and more.

Homepage-environment-test

Environment

We’ve launched a new biotech studio in Monaco focused on environmental applications. Investments and projects in this space are in the pipeline and currently under evaluation.

Homepage-sustainable-test

Sustainable manufacturing

We’ve made a first investment in Biomemory, a startup working on DNA data storage. All of our investments and start-ups created in climate and sustainability innately align with ESG principles.

News

Stay up to date with our latest news and events

eureKARE wins EU grant to lead SYNBEE project

eureKARE wins EU grant to lead SYNBEE project

The European project will enhance the commercial potential of one of today’s most disruptive fields

eureKARE co-founds EonBio to revolutionize drug discovery with pioneering cell-free technology on a chip

eureKARE co-founds EonBio to revolutionize drug discovery with pioneering cell-free technology on a chip

eureKARE announces EonBio as the second company to be supported by its Belgium biomedical start-up studio

eureKARE appoints Anne Lauvergeon as a new Board member

eureKARE appoints Anne Lauvergeon as a new Board member

Ms. Lauvergeon brings an extensive background in the management of large energy corporations (most notably as CEO of Areva), finance, and government.

Let’s build something together!


Whereas you are curious about our projects, investment or biotech studios – we’ve ready to answer any and all quastions.

    Luxembourg

    France

    Belgium

     

    Privacy & Cookies

    France – Belgium – Luxembourg

    Privacy & Cookies